The U.S. Department of Defense has awarded Cedars-Sinai Medical Center $876,000 to support critical biomarker research in non-small cell lung cancer, specifically targeting patients developing resistance to osimertinib. The grant will fund research in Dr. Neil Bhowmick's laboratory, aimed at identifying patients who might benefit from early intervention with Kairos Pharma's experimental drug ENV105.
The research focuses on understanding drug resistance mechanisms in lung cancer, a significant challenge in oncology treatment. By investigating the role of CD105, a protein associated with treatment resistance, researchers hope to develop more precise therapeutic strategies that could improve long-term patient outcomes.
ENV105, Kairos Pharma's lead candidate, represents an innovative approach to addressing cancer treatment resistance. The antibody targets CD105, a protein that becomes elevated during standard cancer therapies and can lead to disease relapse. This research could potentially revolutionize how clinicians approach treatment-resistant lung cancer by enabling more personalized and effective interventions.
The grant underscores the ongoing commitment of the Department of Defense to support advanced medical research that addresses critical unmet medical needs. For lung cancer patients who develop resistance to existing treatments, this research offers hope for more targeted and effective therapeutic approaches.
